Capstone Capital Management Ltd Takes Position in Pfizer Inc. $PFE

Capstone Capital Management Ltd acquired a new position in Pfizer Inc. (NYSE:PFE) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 29,669 shares of the biopharmaceutical company’s stock, valued at approximately $833,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. CFS Investment Advisory Services LLC grew its position in Pfizer by 2.4% during the first quarter. CFS Investment Advisory Services LLC now owns 21,198 shares of the biopharmaceutical company’s stock worth $584,000 after buying an additional 492 shares in the last quarter. W Advisors LLC acquired a new position in Pfizer in the 1st quarter valued at approximately $263,000. Seelaus Asset Management LLC acquired a new position in Pfizer in the 1st quarter valued at approximately $318,000. Greenwood Capital Associates LLC lifted its position in shares of Pfizer by 1.6% in the 1st quarter. Greenwood Capital Associates LLC now owns 55,999 shares of the biopharmaceutical company’s stock worth $1,572,000 after acquiring an additional 869 shares during the period. Finally, Staley Capital Advisers Inc. lifted its position in shares of Pfizer by 2.7% in the 1st quarter. Staley Capital Advisers Inc. now owns 2,035,654 shares of the biopharmaceutical company’s stock worth $57,161,000 after acquiring an additional 54,140 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer continues to draw attention from income investors because of its large dividend payout, and some market commentary frames the stock as a potential value play for buyers seeking yield. How Pfizer’s (PFE) Dividend Record Separates Tax Treatment From Business Momentum
• Positive Sentiment: Analyst and media coverage continues to highlight Pfizer as an attractively priced healthcare stock after the recent FDA approval for IBRANCE, which could support the investment case if pipeline progress continues. Is Pfizer (PFE) Undervalued After IBRANCE Won A New FDA Approval?
• Neutral Sentiment: Pfizer is also attracting broad investor attention in screening and “most searched” lists, which reflects heightened trading interest but does not by itself change the fundamentals. Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
• Negative Sentiment: JPMorgan lowered its price target on Pfizer and kept a neutral stance, signaling limited near-term upside in the bank’s view and likely contributing to the stock’s weakness. Pfizer price target cut news
• Negative Sentiment: Several articles questioned whether Pfizer’s dividend is riskier than it appears, which can dampen enthusiasm even though the stock is known for income appeal. Opinion: Pfizer’s Dividend Is Riskier Than You Might Think
• Negative Sentiment: News coverage about structural problems at Pfizer’s former headquarters added another negative headline, even though one report said the issues were related to construction rather than steel quality. ‘Failures happen during construction’: Office-to-residential conversions are all over NYC, but failures usually get fixed before they get worse

Pfizer Stock Performance

Pfizer stock opened at $24.05 on Thursday. The firm has a market capitalization of $137.05 billion, a P/E ratio of 18.36 and a beta of 0.35. The stock has a fifty day moving average price of $25.46 and a two-hundred day moving average price of $26.20. Pfizer Inc. has a 52-week low of $23.11 and a 52-week high of $28.75. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.2%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio is currently 131.30%.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of research reports. Citigroup boosted their price objective on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Bank of America lowered their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. CICC Research began coverage on shares of Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price objective for the company. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a report on Tuesday, June 23rd. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $28.56.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.